Hyloris Pharmaceuticals SA

ENXTBR:HYL Stock Report

Mkt Cap: €330.4m

Hyloris Pharmaceuticals Past Performance

Past criteria checks 0/6

Hyloris Pharmaceuticals's earnings have been declining at an average annual rate of -15.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 63.6% per year.

Key information


Earnings growth rate


EPS growth rate

Pharmaceuticals Industry Growth12.3%
Revenue growth rate63.6%
Return on equity-25.6%
Net Margin-404.9%
Next Earnings Update14 Mar 2024

Recent past performance updates

Recent updates

Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Mar 08
Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Earnings and Revenue History

ENXTBR:HYL Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 233-12512
31 Mar 233-12411
31 Dec 223-11410
30 Sep 223-1039
30 Jun 223-838
31 Mar 223-1037
31 Dec 213-1235
30 Sep 212-1224
30 Jun 211-1213
31 Mar 211-1023
31 Dec 200-723
30 Sep 200-832
30 Jun 200-832
31 Mar 200-612
31 Dec 190-511
31 Dec 180-615
31 Dec 170-422

Quality Earnings: HYL is currently unprofitable.

Growing Profit Margin: HYL is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: HYL is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.

Accelerating Growth: Unable to compare HYL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HYL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).

Return on Equity

High ROE: HYL has a negative Return on Equity (-25.58%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies